TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37800374
Drug: Admission to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Admission to the nearest primary stroke center (PSC) prioritizing intravenous thrombolysis (IVT)
Study: 37800415
Drug: High-Dose Trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose Trivalent Influenza Vaccine (HD-TIV)
Study: 37800415
Drug: Standard-Dose Quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-Dose Quadrivalent Influenza Vaccine (SD-QIV)
Study: 37800597
Drug: Nivasorexant 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivasorexant 100 mg administered twice daily (b.i.d.)
Study: 37800597
Drug: Cocktail of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail of flurbiprofen (50 mg, CYP2C9), omeprazole (20 mg, CYP2C19), midazolam (2 mg, CYP3A4)
Study: 37800633
Drug: Long-acting muscarinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting muscarinic antagonist/long-acting β-agonist
Study: 37800766
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy with osimertinib
Study: 37801046
Drug: Zanamivir inhalation
Normalized name: zanamivir Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanamivir inhalation
Study: 37801266
Drug: Zibotentan 5
Normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zibotentan 5 mg (single oral dose)
Study: 37801315
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) and radiation therapy (RT) plus docetaxel
Study: 37801358
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (existing oral care routines)
Study: 37801454
Drug: Dietary modification
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary modification as part of lipid-lowering therapy
Study: 37801658
Drug: Intermittently Scanned
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections
Study: 37801674
Drug: HER3-DXd 1.6-8.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: HER3-DXd 1.6-8.0 mg/kg intravenously once every 3 weeks
Study: 37801707
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy (rituximab + chlorambucil)
Study: 37801789
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral iron supplementation (FeSO4)
Study: 37802038
Drug: Single-dose intrahippocampal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intrahippocampal delivery of cryopreserved, post-mitotic, medial ganglionic eminence (MGE) pallial-type GABAergic interneurons.
Study: 37802566
Drug: PGT121 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGT121 + VRC07-523LS (treatment one; n=6)
Study: 37802566
Drug: PGDM1400 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGDM1400 + VRC07-523LS (treatment two; n=6)
Study: 37802566
Drug: 10-1074 +
Normalized name: NRX-1074
DrugBank: NRX-1074 (DB11784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-1074 + VRC07-523LS (treatment three; n=6)
Study: 37802566
Drug: PGDM1400 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGDM1400 + PGT121 + VRC07-523LS (treatment four; n=9)
Study: 37802608
Drug: Short-course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiotherapy (SCRT) combined with chemotherapy and PD-1 inhibitor (toripalimab)
Study: 37802619
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation therapies (OATs)
Study: 37802620
Drug: Physiotherapy sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy sessions (9 sessions) with pain ratings 4-7 out of 10 for 9 weeks and 0-2 for 3 weeks, including 15 min of manual therapy; non-supervised exercises 2×/week with physiotherapy and 3×/week without physiotherapy.
Study: 37802679
Drug: Chlormethine (CL)
Normalized name: chlormethine
DrugBank: Mechlorethamine (DB00888)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlormethine (CL) gel
Study: 37803096
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy prior to robot-assisted therapy
Study: 37803096
Drug: Sham mirror
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham mirror therapy prior to robot-assisted therapy
Study: 37803368
Drug: Beclometasone dipropionate/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/G) 100/6/10 µg, two inhalations twice-daily for 6 weeks after switching from high-dose ICS/LABA.
Study: 37803368
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled corticosteroid/long-acting β-agonist (ICS/LABA) regimen prior to switching.
Study: 37803467
Drug: Compassion and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compassion and Mindfulness Intervention for RA (MITIG.RA) + Treatment as Usual (TAU)
Study: 37803473
Drug: Expression level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expression level of placental omega-3 receptors
Study: 37803759
Drug: High-fiber diet
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber diet (≥20 g/d DF)
Study: 37804162
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training using cuff weights/dumbbells at light intensity (40%-50% of maximum one repetition, 10-15 repetitions for one to three times a day) for major muscle groups of upper and lower limbs on a weekly basis.
Study: 37804162
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy group (control group).
Study: 37804307
Drug: Aortix therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aortix therapy
Study: 37804430
Drug: Palovarotene 20
Normalized name: palovarotene
DrugBank: Palovarotene (DB05467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palovarotene 20 mg (whole capsule or sprinkled on food)
Study: 37804430
Drug: Palovarotene 20
Normalized name: palovarotene
DrugBank: Palovarotene (DB05467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palovarotene 20 mg
Study: 37804674
Drug: Dalfampridine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalfampridine (10 mg twice daily) plus physiotherapy (twice a week)
Study: 37804765
Drug: B cell
Normalized name: B cell antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: B cell depletion therapy
Study: 37805605
Drug: Thyme honey
Normalized name: THYME
DrugBank: Thyme (DB10983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyme honey oral rinse
Study: 37806074
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction chemotherapy (SIC)
Study: 37806075
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (1000 mg/day)
Study: 37806314
Drug: HU6 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: HU6 150 mg
Study: 37806314
Drug: HU6 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: HU6 300 mg
Study: 37806314
Drug: HU6 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: HU6 450 mg
Study: 37806333
Drug: Drug-eluting balloon
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting balloon (DEB) in the side branch
Study: 37806333
Drug: Drug-eluting stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stent (DES) in the side branch
Study: 37806651
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 mg extended-release daily
Study: 37807179
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g TXA bolus
Study: 37807179
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g bolus + 1 g/8 hours TXA infusion
Study: 37811634
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg once daily with limertinib 160 mg (Part A)
Study: 37811634
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg twice daily with limertinib 80 mg (Part B)
Study: 37811993
Drug: Ad26 mosaic
Normalized name: Ad26.Zebov
DrugBank: VAC-52150 (DB17781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26 mosaic vaccine regimen
Study: 37812229
Drug: Analgesic administration
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic administration
Study: 37812272
Drug: Trauma Focused
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma Focused Cognitive Behavioral Therapy (TF-CBT)
Study: 37812307
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution (BSS) supplementation before intraocular lens (IOL) implantation and before the end of surgery.
Study: 37812381
Drug: Prophylactic norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic norepinephrine 0 µg/kg/min
Study: 37812381
Drug: Prophylactic norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic norepinephrine 0.025 µg/kg/min
Study: 37812381
Drug: Prophylactic norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic norepinephrine 0.05 µg/kg/min
Study: 37812381
Drug: Prophylactic norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic norepinephrine 0.075 µg/kg/min
Study: 37812381
Drug: Prophylactic norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic norepinephrine 0.1 µg/kg/min
Study: 37812429
Drug: XEN1101 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN1101 25 mg
Study: 37812429
Drug: XEN1101 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN1101 20 mg
Study: 37812429
Drug: XEN1101 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN1101 10 mg
Study: 37812679
Drug: Darolutamide 600
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darolutamide 600 mg plus ADT and docetaxel
Study: 37813304
Drug: Continuous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous oxytocin infusion (16 hours, with a 4 hours pause in between infusions)
Study: 37813418
Drug: Early antihypertensive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antihypertensive treatment started within 24-48 hours aimed at reducing systolic blood pressure by 10%-20% within the first 24 hours and achieving mean blood pressure <140/90 mm Hg within seven days.
Study: 37813418
Drug: Delayed antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antihypertensive treatment starting on day 8 aimed at achieving mean blood pressure <140/90 mm Hg.
Study: 37813959
Drug: Dinutuximab beta
Normalized name: dinutuximab beta
DrugBank: Dinutuximab (DB09077)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dinutuximab beta (continuous infusion over 10 days of each cycle, for up to five cycles)
Study: 37814129
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg escitalopram (n=17)
Study: 37814541
Drug: Olme/Amlo/Rosu 20/5/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olme/Amlo/Rosu 20/5/5 mg
Study: 37814541
Drug: Olme/Amlo/Rosu 20/5/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olme/Amlo/Rosu 20/5/10 mg
Study: 37814541
Drug: Amlo/Olme 20/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlo/Olme 20/5 mg
Study: 37814892
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (SBP target 130 to <150 mm Hg)
Study: 37815096
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy for 24 weeks
Study: 37815094
Drug: Tighter glycaemic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tighter glycaemic control (≤ 5.0 to 5.1 mmol/L fasting plasma glucose; ≤ 6.7 to 7.4 mmol/L postprandial)
Study: 37815254
Drug: CGRP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CGRP infusion (1.5 µg/min) for 20 minutes
Study: 37815398
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg telavancin
Study: 37815489
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of plasma microbial cell-free DNA sequencing and usual care testing
Study: 37815790
Drug: Antibiotic use
Normalized name: Antibiotics for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic use in NICU
Study: 37815957
Drug: Prophylactic psychopharmacological
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic psychopharmacological treatment (mainly first-generation antipsychotics)
Study: 37816198
Drug: PROStep intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PROStep intervention with weekly text message-based symptom surveys and passive activity monitoring using a wearable accelerometer; additional text-based active choice prompt in one arm
Study: 37816249
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of K MAX and A F
Study: 37816249
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of K MAX and P MIN
Study: 37816249
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of K 2F and R mB
Study: 37816489
Drug: Silane-Adhesive treatment
Normalized name: silane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silane-Adhesive treatment (application of a silane coupling agent after acid etching)
Study: 37816489
Drug: Sandblast-Silane-Adhesive treatment
Normalized name: silane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandblast-Silane-Adhesive treatment (intra-oral sandblasting followed by silane application)
Study: 37816489
Drug: Control (No
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (No additional treatment)
Study: 37816552
Drug: Multimodal prehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal prehabilitation combined with ERAS, at least 2 weeks before gastrectomy, including physical and respiratory training, nutritional support, and therapy and psychosocial treatment
Study: 37816552
Drug: ERAS pathway
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERAS pathway treatment
Study: 37816561
Drug: Weekly text
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly text messaging encouraging exclusive breastfeeding plus in-person individual motivational interviews at weeks 2, 6, and 10.
Study: 37816943
Drug: Sequential arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential arm
Study: 37817124
Drug: Bilateral sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral sequential TBS (continuous TBS to the right and intermittent TBS to the left DLPFC)
Study: 37817124
Drug: Bilateral sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral sequential TBS
Study: 37817147
Drug: Day patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day patient treatment (DP) after short inpatient (IP) stabilization
Study: 37817147
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment (IP) as usual
Study: 37817255
Drug: Doxapram therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram therapy
Study: 37817267
Drug: Behavioral sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral sleep extension intervention (sleep coaching) for 8 weeks followed by monthly coaching for 2 months
Study: 37817267
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education (control) for 8 weeks followed by monthly education for 2 months
Study: 37817565
Drug: Neoadjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiation (CRT) regimen consisting of 2 cycles of chemotherapy with DCF (docetaxel, cisplatin, and 5-fluorouracil) followed by preoperative CRT with oxaliplatin, continuous 5FU and radiotherapy (45 Gy in 25 fractions of 1.8 Gy, 5 fractions per week for 5 weeks)
Study: 37818279
Drug: Guideline-adherent treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-adherent treatments (exercise, education, dietary weight management)
Study: 37818279
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment pathways
Study: 37818791
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care interventions delivered by healthcare professionals (general physicians, pharmacists, nurses, geriatricians)
Study: 37819503
Drug: Proposed adaptive
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed adaptive dosing strategy
Study: 37819505
Drug: Guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 100 mg every 4 weeks (Q4W) or at week 0, week 4, then Q8W
Study: 37819691
Drug: Standard ICI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ICI therapy (control group)
Study: 37819936
Drug: Low-dose gemcitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose gemcitabine (100 mg/m2 on days 1, 8, and 15) combined with CHK1 inhibitor LY2880070 (50 mg orally twice daily on days 2-6, 9-13, and 16-20 of each 21-day cycle)
Study: 37820029
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg followed by placebo
Study: 37820029
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg followed by placebo
Study: 37820358
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy group (10 participants)
Study: 37821096
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg CBD (0:1 CBD:THC)
Study: 37821096
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg CBD (1:1 CBD:THC)
Study: 37821096
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg CBD (2:1 CBD:THC)
Study: 37821096
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg CBD (3:1 CBD:THC)
Study: 37821122
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided deposit lavage plus subacromial injection of 20 mg triamcinolone acetonide and 9 mL 1% lidocaine hydrochloride (lavage+steroid)
Study: 37821122
Drug: Sham lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham lavage plus subacromial injection of 20 mg triamcinolone acetonide and 9 mL 1% lidocaine hydrochloride (sham lavage+steroid)
Study: 37821122
Drug: Sham lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham lavage plus subacromial injection of 10 mL 1% lidocaine hydrochloride (sham)
Study: 37821131
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg potassium canrenoate every 6 hours until organ procurement
Study: 37821242
Drug: Metastasis-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metastasis-directed therapy (MDT) and 6 months of androgen deprivation therapy (ADT)
Study: 37821342
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at ZT8
Study: 37821342
Drug: Sufentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil infusion at ZT8
Study: 37821461
Drug: Antipsychotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics plus metformin
Study: 37821461
Drug: Antipsychotics alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics alone
Study: 37821472
Drug: Latency-reversing agent
Normalized name: Reversion Acne Control Toner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latency-reversing agent vorinostat, ChAdV63.HIVconsv and MVA.HIVconsv vaccines
Study: 37821913
Drug: Multimodal intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal intervention based on Cognitive Behavior Therapy
Study: 37821968
Drug: Central venous
Normalized name: ACCUGUIDE CENTRAL VENOUS CATHETER KIT C1409AK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central venous oxygen saturation (ScvO2)-based goal-directed therapy
Study: 37821968
Drug: Standard fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fluid loading-based goal-directed therapy
Study: 37822243
Drug: Low-molecular-weight fucoidan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight fucoidan (LMF) as a supplement to therapy.
Study: 37822710
Drug: Exercise (60-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise (60- to 75-min daily)
Study: 37823031
Drug: TransCon CNP
Normalized name: TransCon CNP
DrugBank: ACP-015 (DB17824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TransCon CNP 100 μg CNP/kg/week
Study: 37823034
Drug: TV-46046 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV-46046 (120 mg/0.3 mL)
Study: 37823034
Drug: Depo-subQ Provera
Normalized name: depo-subQ provera
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo-subQ Provera 104 (104 mg/0.65 mL)